Table 3 Results of the intention-to-treat analysis comparing clinical outcomes between treatment groups
Mean (SD) for each group | Adjusted mean difference between groups (95 % CI) | |||||
|---|---|---|---|---|---|---|
Graston | SMT | Placebo | Graston vs MT | Graston vs placebo | SMT vs placebo | |
Disability (0-100)* | ||||||
Baseline | 29.6 (11.0) | 27.2 (10.0) | 28.1 (9.8) | - | - | - |
1 week | 22.6 (11.8) | 22.3 (10.0) | 23.7 (12.1) | -0.58 (-4.7,3.6) | -1.9 (-5.8,2.0) | -1.3 (-5.8,2.0) |
1 month | 18.1 (12.0) | 19.8 (11.7) | 21.5 (12.3) | -3.4 (-7.7, 0.9) | -4.5 (-8.6, -0.4) | -1.1 (-5.7, 3.6) |
3 months | 16.2 (13.1) | 21.0 (14.3) | 18.7 (15.0) | -4.6 (-9.5, 0.4) | -2.1 (-7.0, 2.8) | 2.5 (-2.9, 7.9) |
6 months | 16.2 (13.1) | 18.2 (14.2) | 16.9 (14.1) | -1.9 (-6.9, 2.9) | -0.4 (-4.9, 4.2) | 1.6 (-3.7, 6.9) |
12 months | 16.3 (13.5) | 21.2 (16.0) | 16.1 (16.3) | -4.8 (-10.5, 0.9) | -1.2 (-6.8, 4.4) | 3.6 (-2.5, 9.7) |
Pain intensity (0-10)† | ||||||
Baseline | 5.7 (2.1) | 5.5 (2.0) | 5.5 (1.9) | - | - | - |
1 week | 4.7 (1.9) | 5.1 (2.0) | 4.7 (1.8) | -0.3 (-1.2, 0.5) | 0.1 (-0.7, 0.8) | 0.4 (-0.5, 1.2) |
1 month | 3.4 (1.9) | 4.3 (2.0) | 4.2 (2.4) | -1.0 (-1.9, -0.2) | -0.9 (-1.7, -0.1) | 0.1 (-0.8, 1.0) |
3 months | 3.2 (2.6) | 4.0 (2.2) | 3.5 (2.3) | -0.8 (-1.8, 0.1) | -0.3 (-1.3, 0.6) | 0.5 (-0.5, 1.5) |
6 months | 3.5 (2.5) | 3.6 (2.2) | 3.6 (2.5) | -0.4 (-1.4, 0.7) | -0.2 (-1.2, 0.8) | 0.2 (-1.0, 1.3) |
12 months | 3.2 (2.3) | 3.8 (2.4) | 3.3 (2.5) | -0.8 (-1.9, 0.3) | -0.4 (-1.5, 0.7) | 0.4 (-0.8, 1.6) |